2018
Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008–2011
Wilson LE, Pollack CE, Greiner MA, Dinan MA. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008–2011. Breast Cancer Research And Treatment 2018, 170: 361-371. PMID: 29536319, DOI: 10.1007/s10549-018-4746-6.Peer-Reviewed Original ResearchConceptsMedical oncologistsPhysician characteristicsBreast cancerGenomic testingMedicare beneficiariesAmerican Medical Association Physician Master FileNode-negative breast cancerEarly-stage breast cancerReceipt of testingMethodsRetrospective cohort studyYear of diagnosisPhysician-level factorsPhysician-level characteristicsMultivariable regression modelsAdjuvant chemotherapyCohort studyRS testingOptimal careResultsA totalStudy criteriaSurgical oncologySurgical proceduresHigher oddsMAIN OUTCOMELower odds
2017
Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset
Harowicz MR, Robinson TJ, Dinan MA, Saha A, Marks JR, Marcom PK, Mazurowski MA. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. Breast Cancer Research And Treatment 2017, 162: 1-10. PMID: 28064383, PMCID: PMC5909985, DOI: 10.1007/s10549-016-4093-4.Peer-Reviewed Original ResearchConceptsIntermediate-risk diseaseOncotype DX recurrence scoreHigh-risk diseaseDX recurrence scoreODX RSReceptor statusRecurrence scoreSurrogate markerProgesterone receptor statusInvasive breast cancerEstrogen receptor statusHigh-risk groupOngoing clinical trialsMagee EquationsPresence of patientsAdjuvant chemotherapyClinicopathologic dataRetrospective studyTumor sizeHER2 statusHistopathologic variablesClinical trialsBreast cancerPatient managementAdditional independent validation
2016
Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population.
Dinan M, Mi X, Reed S, Lyman G, Curtis L. Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population. Journal Of Clinical Oncology 2016, 34: 32-32. DOI: 10.1200/jco.2016.34.7_suppl.32.Peer-Reviewed Original ResearchHigh-risk diseaseOncotype DXRisk diseaseChemotherapy costsODX testingBreast cancerAdjuvant chemotherapyRisk womenPatient outcomesEnd Results-Medicare dataEarly-stage breast cancerER-positive breast cancerReal-world clinical practiceIntermediate-risk womenSEER-Medicare populationLow-risk diseaseHigh-risk womenPositive breast cancerWorld clinical practiceActual patient outcomesTotal Medicare paymentsNCCN guidelinesOverall cohortMultivariable analysisPathologic features
2015
Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer
Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Carey LA, Troester MA, Wheeler SB. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. Journal Of Clinical Oncology 2015, 34: 130-138. PMID: 26598755, PMCID: PMC4872005, DOI: 10.1200/jco.2015.63.2489.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBlack or African AmericanBreast NeoplasmsClinical Trials, Phase II as TopicConfounding Factors, EpidemiologicErbB ReceptorsFemaleGene Expression ProfilingHealthcare DisparitiesHumansInsurance CoverageLymphatic MetastasisMiddle AgedMolecular Targeted TherapyNeoplasm StagingNorth CarolinaPoisson DistributionPractice Guidelines as TopicPrecision MedicinePredictive Value of TestsResearch DesignRisk AssessmentRisk FactorsConceptsNode-positive breast cancerNon-black womenODX testingNode-negative patientsBreast cancerOncotype DXBlack patientsRacial disparitiesEarly-stage breast cancerCarolina Breast Cancer StudyGuideline-concordant careNode-positive patientsCancer care qualityPopulation-based studyOncotype DX testingQuality of careNorth Carolina womenLow socioeconomic statusMedium tumor sizeBlack womenBreast Cancer StudyAdjuvant chemotherapyMore comorbiditiesConcordant careTumor sizeAssociation Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009
Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. JAMA Oncology 2015, 1: 1098. PMID: 26313372, DOI: 10.1001/jamaoncol.2015.2722.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGenetic TestingGuideline AdherenceHumansInsurance BenefitsMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPatient SelectionPhenotypePractice Guidelines as TopicPredictive Value of TestsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsReceipt of chemotherapyLower chemotherapy useHigh-risk diseasePatients 70 yearsChemotherapy useBreast cancerRecurrence scoreMedicare beneficiariesNational Comprehensive Cancer Network guidelinesEarly-stage breast cancerConsideration of chemotherapyLow-risk diseaseOverall chemotherapy useIncident breast cancerLow-risk patientsRetrospective cohort studyHigh-risk patientsPrespecified subgroup analysisUse of chemotherapyAdditional prognostic informationEnd Results (SEER) dataInvasive breast cancerRS assayNCCN riskAdjuvant chemotherapyRacial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing
Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Troester MA, Carey LA, Wheeler SB. Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. Breast Cancer Research And Treatment 2015, 153: 191-200. PMID: 26216535, PMCID: PMC4562432, DOI: 10.1007/s10549-015-3518-9.Peer-Reviewed Original ResearchConceptsAdjuvant chemotherapy initiationChemotherapy initiationRisk scoreODX testingCarolina Breast Cancer StudyIntermediate-risk groupRacial variationBreast cancer patientsPopulation-based studyHigh-risk groupLarger tumor sizeLow-risk groupOncotype DX testingRacial differencesNorth Carolina womenBreast Cancer StudyAdjuvant chemotherapyTumor sizeCancer patientsRelative riskRisk groupsBreast cancerPoisson regressionYounger agePhase IIIInitial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009
Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. JAMA Oncology 2015, 1: 158-166. PMID: 26181015, DOI: 10.1001/jamaoncol.2015.43.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGuideline AdherenceHealthcare DisparitiesHumansMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhenotypePractice Guidelines as TopicPractice Patterns, Physicians'Predictive Value of TestsRacial GroupsResidence CharacteristicsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsIntermediate-risk diseaseBreast cancerRecurrence scoreClinical practiceNode-negative breast cancerNational Comprehensive Cancer NetworkAdjuvant chemotherapy useIncident breast cancerComprehensive Cancer NetworkEnd Results (SEER) dataHigh-grade diseaseRetrospective observational studyRoutine clinical practiceTumor histologic characteristicsMedicare coverage decisionsAdjuvant chemotherapyChemotherapy useN1 diseaseMost patientsComorbid conditionsMultivariable analysisRS assayClinical variablesStudy criteriaBlack race
2014
Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007.
Dinan M, Mi X, Reed S, Lyman G, Curtis L. Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007. Journal Of Clinical Oncology 2014, 32: 309-309. DOI: 10.1200/jco.2014.32.30_suppl.309.Peer-Reviewed Original ResearchReceipt of chemotherapyChemotherapy utilizationOncotype DXRisk diseaseBreast cancerODX testingEarly-stage estrogen receptor-positive breast cancerEstrogen receptor-positive breast cancerReceptor-positive breast cancerEarly-stage breast cancerER-positive breast cancerIntermediate-risk diseaseHigh-risk patientsHigh-risk diseasePositive breast cancerBreast cancer populationAdjuvant chemotherapyNCCN guidelinesRisk patientsPathologic featuresRandomized trialsStudy criteriaCancer populationObservational studyRetrospective analysis